



February 8, 2025

Dept. of Corporate Services  
**BSE Ltd.**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001.

Listing Department  
**National Stock Exchange of India Ltd.**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051.

**BSE Scrip Code : 524735**

**NSE Symbol : HIKAL**

**Subject: Hikal’s Jigani Unit has completed US FDA Inspection with observations.**

Ref : Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, the Company announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru, Karnataka. The inspection, conducted from 3<sup>rd</sup> February 2025 till 7<sup>th</sup> February 2025, concluded with six observations. The Company will address the observations and submit its response to the USFDA within the stipulated timeframe.

We request you to take the above on record.

Thanking you,

Yours Sincerely,  
**for HIKAL LIMITED,**

**Rajasekhar Reddy**  
**Company Secretary and Compliance Officer**

**Hikal Ltd.**

**Admin. Office:** Great Eastern Chambers, 6<sup>th</sup> Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91–22–6277 0299, + 91–22–6866 0300

**Regd. Office:** 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028